Catalyst Pharmaceuticals Inc (OQ:CPRX)
Business Focus: Biopharmaceuticals
| Sector: Healthcare | Industry: Pharmaceuticals |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 355 ALHAMBRA CIRCLE, SUITE 801 CORAL GABLES FL 33134 |
| Tel: | N/A |
| Website: | https://catalystpharma.com |
| IR: | See website |
| Key People | ||
| Richard J. Daly Chief Executive Officer, Director | Michael Wayne Kalb Chief Financial Officer, Executive Vice President, Treasurer | Steven R. Miller Executive Vice President, Chief Operating Officer, and Chief Scientific Officer |
| Jeffrey Del Carmen Executive Vice President, Chief Commercial Officer | Brian D. Elsbernd Chief Compliance Officer, Chief Legal Officer | Gary Ingenito Chief Medical Officer and Regulatory Officer | Preethi Sundaram Chief Strategy Officer |
| Business Overview |
| Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for children ages six to seventeen. The Company is also marketing FYCOMPA (perampanel) CIII as a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Its portfolio also includes AGAMREE (vamorolone) an oral suspension 40 mg/ml for the treatment of Duchenne Muscular Dystrophy (DMD). The vamorolone is a corticosteroid treatment for patients suffering from DMD. |
| Financial Overview |
| For the three months ended 31 March 2024, Catalyst Pharmaceuticals Inc revenues increased 15% to $98.5M. Net income decreased 21% to $23.3M. Revenues reflect License and other revenue increase of 10% to $68K. Net income was offset by Selling, general and adminis - Balancing increase of 44% to $39.2M (expense), Stock-based Compensation in SGA increase from $2.6M to $7.7M (expense), Amortization of intangible assets increase of 43% to $9.3M (expense). |
| Employees: | 167 as of Feb 28, 2024 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $1,656M as of Mar 31, 2024 |
| Annual revenue (TTM): | $411.35M as of Mar 31, 2024 |
| EBITDA (TTM): | $114.04M as of Mar 31, 2024 |
| Net annual income (TTM): | $65.12M as of Mar 31, 2024 |
| Free cash flow (TTM): | $163.10M as of Mar 31, 2024 |
| Net Debt Last Fiscal Year: | N/A |
| Shares outstanding: | 118,115,079 as of May 6, 2024 |
| Index Membership: | S&P 600 Small Cap |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.